Co-administration of phospholipid emulsion with first dose bacteriocidal antibiotic may retard progression of the sepsis response in gram negative septicaemia

Medical Hypotheses

Volumn 83, Issue 5, 2014, Pages 563-565

  Harvey, Martyn ^a   Cave, Grant ^b  

^a WAIKATO HOSPITAL   (New Zealand)

^b Tamworth Base Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LIPID EMULSION; LIPOPOLYSACCHARIDE; PHOSPHOLIPID; ANTIINFECTIVE AGENT; EMULSION; ENDOTOXIN; HIGH DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL CELL WALL; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; DISEASE SEVERITY; DRUG FORMULATION; DRUG RELEASE; ENDOTOXEMIA; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; NONHUMAN; SEPSIS; SEPTIC SHOCK; TREATMENT RESPONSE; BACILLUS; CELL WALL; CHEMISTRY; DRUG EFFECTS; EMULSION; HEMODYNAMICS; HUMAN; INFLAMMATION; METABOLISM; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACILLUS; CELL WALL; EMULSIONS; ENDOTOXINS; GRAM-NEGATIVE BACTERIA; HEMODYNAMICS; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; LIPOPROTEINS, HDL; PHOSPHOLIPIDS; SEPSIS;

EID: 84908233142     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.08.024     Document Type: Article

References (23)

1. Herzum I., Renz H. Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem 2008, 15:581-587.
2. Bellomo R. The cytokine network in the critically ill. Anaesth Intensive Care 1992, 20:288-302.
3. Pallua N., von Heimburg D. Pathogenic role of interleukin-6 in the development of sepsis. Part 1: Study on a standardized contact burn murine model. Crit Care Med 2003, 31:1490-1494.
4. Kox W., Volk T., Kox S., Volk H. Immunomodulatory therapies in sepsis. Intensive Care Med 2000, 26:124-128.
5. Ranieri V., Thompson B., Barie P., et al. For the PROWESS-SHOCK study group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 31:2055-2064.
6. Donta S.T., Peduzzi P., Cross A.S., et al. The federal hyperimmune immunoglobulin trial study group immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. J Infect Dis 1996, 174:537-543.
7. Lynn M., Rossignol D., Wheeler J., et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003, 15:631-639.
8. Ronco C., Piccinni P., Kellum J. Rationale of extracorporeal removal of endotoxin in sepsis: theory, timing and technique. Contrib Nephrol 2010, 167:25-34.
9. Rachoin J., Schorr C., Dellinger R. Targeting endotoxin in the treatment of sepsis. Subcell Biochem 2010, 53:323-328.
10. Parker T., Levine D., Chang J., Laxer J., Coffin C., Rubin A. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun 1995, 63:253-258.
11. Harris H., Grunfeld C., Feingold K., et al. Human VLDL and chylomicrons can protect against endotoxin induced death in mice. J Clin Invest 1990, 86:696-701.
12. Levine D., Parker T., Donnelly T., et al. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A 1993, 90:12040-12044.
13. Winchell W., Hardy J., Levine D., et al. Effect of administration of phospholipid emulsion on the initial response of horses administered endotoxin. Am J Vet Res 2002, 63:1370-1378.
14. Goldfarb R.D., Parker T.S., Levine D.M., et al. Protein-free phospholipid emulsion treatment improved cardiopulmonary function and survival in porcine sepsis. Am J Physiol Regul Integr Comp Physiol 2003, 284:5507.
15. Dellinger R., Tomayko J., Angus D., et al. Efficacy and safety of a phospholipid emulsion (GR270773) in gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose finding clinical trial. Crit Care Med 2009, 37:2929-2938.
16. Rivers E., Nguyen B., Havstad S., et al. Early goal directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377.
17. Kushi H., Miki T., Okamaoto K., Saito T., Tanjoh K. Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit Care 2005, 9:R653-61.
18. Nemoto H., Nakamoto H., Okada H., et al. Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif 2001, 19:361-369.
19. Uriu K., Osajima A., Hiroshige K., et al. Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin B immobilized fiber ameliorates systemic circulatory disturbance in patients with septic shock. Am J Kidney Dis 2002, 39:937-947.
20. Cruz D., Antonelli M., Fumagalli R., et al. Early use of polymyxin B hemoperfusion in abdominal septic shock. JAMA 2009, 301:2445-2452.
21. Morrison D., Bucklin S. Evidence for antibiotic mediated endotoxin release as a contributing factor to lethality in experimental gram-negative sepsis. Scand J Infect Dis 1996, 101:3-8.
22. Holzheimer R. Antibiotic induced endotoxin release and clinical sepsis: a review. J Chemother 2001, 1:159-172.
23. DE Gaudio M., Chippini E., Galli L., DE Martino M. Therapeutic management of bacterial meningitis in children. A systematic review and comparison of published guidelines from a European perspective. J Chemother 2010, 22:226-237.